Member Info for aim999

Just a waiting game.... I think AGM in a month, I'd expect some news flow and SP higher by then

This will adjust back and continue its assent. We have a big wealthy shareholder that understands the value and is waiting to realise the value. Need flow should be strong going forward

No surprise to me ..... Bargain prices at the moment ....

Buying and good trading over the pond

You, me, slater, and the richest dude in Asia! And a select few others...

Maybe you need to fully read the accounts and have an understanding of JV accounting

I suspect they will keep the news flow coming to show the value here

http://www.business.nasdaq.com/discover/Nasdaq-at-Times-Square/bell-ceremonies live in 30 mins

http://www.ftchinese.com/story/001066581?full=y

当2001年杜莹(Samantha Du)带着创建一家制药公司的使命回到祖国时，她的举动似乎像是一个可怕的错误。 她放弃了在美国的优渥生活。她在那里已经生活了12年，先是读博士，后来在辉瑞(Pfizer)工作，期间不断获得晋升。回到中国，当她设法自己创业时，她反倒感觉自己像一个外国人。 最糟糕的时刻是在一次商务会谈期间——提神饮品只有烈性酒。她回忆道：“每个人都喝到睡着。醒来之后，他们就把合同签了。在他们睡着时，我走出房间哭了一场。我舍弃了一份很有前途的事业，还有恬静的康涅狄格州的大房子。现在，我却在和一群醉汉谈判。” 好几次她都差点放弃，但是被合伙&

Sorry losing track of day of week ... Correct tomorrow .... Hutchison China Meditech Ltd. is a China-based biopharmaceutical company targeting therapies for oncology and immunological diseases. The company plans to offer 6.1 million American Depositary Shares (ADS). Each ADS represents one-half of an ordinary share. The company’s ordinary shares already trade on London’s AIM market at a price equivalent $16.33 (as of March 3rd). At that price the company expects to raise $100 million. Lead managers for the offering are BofA/Merrill Lynch and Deutsche Bank. Co-managers include Stifel, Canaccord Genuity, Panmure Gordon, and CITIC Securities. Shares are expected to begin trading Thursday on the Nasdaq under the ticker symbol HCM.

A nice bit of buying ahead of US listing later today

Results pres

Have they got the years mixed up or are they reporting next year

Amazing and the mm are holding this firm ...... Someone increasing their % Wonder who. ;)

http://www.ft.com/cms/s/0/33053610-f0bf-11e3-8f3d-00144feabdc0.html#axzz34IjJskwj

Prevailing Medtronic of the US takeover talk continued to put a spring in the step of replacement hip and knee group Smith & Nephew, 25p higher at 1100p. Intensifying rumours that private equity players Blackrock and Warburg Pincus are stalking aesthetics and skin care company Sinclair IS Pharma helped it rise 3.5p to 33.5p. Legendary investor George Soros recently spent £9million taking his stake above 5 per cent and dealers believe he could have snapped up some more stock yesterday when a overhang was cleared. Sinclair’s attraction is that it owns Silhouette, a company that has found a replacement for botox. Silhouette Soft is a £1,200 anti-ageing treatment that uses dissolvable thread to beat wrinkles. Any predator will have to pay 45p-plus a share to stand a chance of gaining control.

Looking good

I think priorities are to get to break even/profit and brand building. That's were the placing money went on design work and marketing ... I think if you go back in the RNS earlier in 2013 the CEO talks about potentially selling a brand to a major at many multiples of the current market cap. Imaging if bes got offered 30m for redleg rum ( a growing category) that would be the jackpot ..... The fact that we have a few high % shareholders would make it more difficult to buy the whole company, unless the price is right.

I don't think production is a problem as I think they use a third party to manufacture. I don't think they have a factory & now they use a distributor to store and distribute. Maybe Brian smith knows more.